Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia

Laurent M. A. Favié,Cacha M. P. C. D. Peeters-Scholte,Anouk Bakker,Huibert Tjabbes,Toine C. G. Egberts,Frank van Bel,Carin M. A. Rademaker,Peter Vis,Floris Groenendaal
DOI: https://doi.org/10.1038/s41390-019-0587-1
IF: 3.953
2019-10-02
Pediatric Research
Abstract:Neonatal encephalopathy following perinatal asphyxia is a leading cause for neonatal death and disability, despite treatment with therapeutic hypothermia. 2-Iminobiotin is a promising neuroprotective agent additional to therapeutic hypothermia to improve the outcome of these neonates.
pediatrics
What problem does this paper attempt to address?